和铂医药连续两年盈利,溢利下滑逾八成至277.8万美元,对外授权仍是收入支柱

时代财经
01 Apr

本文来源:时代财经 作者:文若楠图片来源:图虫创意“对公司来说,2024年非常复杂且有挑战,但也带来很多机会。”在4月1日上午召开的2024年业绩发布会上,和铂医药-B(02142.HK)创始人、CEO王劲松总结道。3月31日晚间,和铂医药发布业绩公告,财报数据显示,2024年,公司录得收入3810万美元,上年同期为8950万美元,同比下降57.43%;录得股东应占溢利277.8万美元,上年同期为...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10